Lomitapide,relief pitcher for patients with homozygous familial hypercholesterolemia

Goldstein JL Brown MS Familial hypercholesterolemia. In: Scriver CR Beaudet AL Sly WS , et al.(eds). The metabolic and molecular bases of inherited disease, 8th ed. New York: McGraw-Hill Information Services Company, 2001, pp. 2863–2913.

Cuchel M Bruckert E Ginsberg HN , et al. Homozygous familial hypercholesterolaemia: New insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 2014; 35: 2146–2157.

Sjouke B Kusters DM Kindt I , et al. Homozygous autosomal dominant hypercholesterolaemia in The Netherlands: Prevalence, genotype–phenotype relationship, and clinical outcome. Eur Heart J 2015; 36: 560–565.

Kolansky DM Cuchel M Clark BJ , et al. Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia. Am J Cardiol 2008; 102: 1438–1443.

Santos RD Gidding SS Hegele RA , et al. Defining severe familial hypercholesterolaemia and the implications for clinical management: A consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. Lancet Diabetes Endocrinol 2016; 4: 850–861.

Cuchel M Meagher EA du Toit Theron H , et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: A single-arm, open-label, phase 3 study. Lancet 2013; 381: 40–46.

Kolovou G, Diakoumakou O, Kolovou V, et al. Microsomal triglyceride transfer protein inhibitor (lomitapide) efficacy in the treatment of patients with homozygous familial hypercholesterolaemia. Eur J Prev Cardiol. 2020; 27: 157–165.

D’Erasmo L Cefalu AB Noto D , et al. Efficacy of lomitapide in the treatment of familial homozygous hypercholesterolemia: Results of a real-world clinical experience in Italy. Adv Ther 2017; 34: 1200–1210.

Roeters van Lennep J Averna M Alonso R . Treating homozygous familial hypercholesterolemia in a real-world setting: Experiences with lomitapide. J Clin Lipidol 2015; 9: 607–617.

Leipold R Raal F Ishak J , et al. The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis. Eur J Prev Cardiol 2017; 24: 1843–1850.